Domestic Pharma Manufacturing Is Growing, but Execution Will Decide What Actually Comes Online

Domestic pharmaceutical manufacturing is moving from a policy conversation to a project execution challenge.

In recent weeks, the FDA selected seven companies for its PreCheck Pilot Program, an initiative designed to support U.S. pharmaceutical manufacturing, increase domestic production capacity, and strengthen supply chain resilience. The goal is to give companies earlier FDA engagement and a more predictable regulatory pathway as they develop new U.S. drug manufacturing facilities.

At the same time, companies are making visible moves to strengthen U.S.-based manufacturing footprints. Resilience recently announced the relocation of its corporate headquarters to Blue Ash, Ohio, along with the expansion of sterile manufacturing capabilities tied to its large West Chester, Ohio facility. That site supports drug product manufacturing, sterile fill-finish, device assembly, packaging, and logistics.

These developments point to the same larger trend: life sciences companies are trying to build more domestic capacity, improve supply chain reliability, and support complex medicines closer to the patients and markets they serve.

But building capacity is not the same as delivering capacity.

For pharmaceutical, biotech, and medical device manufacturers, the real challenge is not only deciding where to manufacture. It is bringing facilities, equipment, utilities, automation, documentation, quality systems, vendors, trained teams, and startup readiness together in a way that works in the real world.

Domestic Manufacturing Is Becoming a Strategic Priority

The push for domestic manufacturing is being driven by several pressures at once.

Drug shortages have kept supply chain resilience in the spotlight. Complex medicines require specialized facilities and tightly controlled processes. Sterile injectables, biologics, cell therapies, and advanced therapies often need manufacturing environments where the margin for error is small. Global supply chain risk, tariff discussions, and geopolitical uncertainty are also encouraging companies to think harder about where and how critical medicines are produced.

The FDA’s PreCheck Pilot Program is important because it recognizes that domestic manufacturing expansion needs more than investment dollars. It needs regulatory predictability, earlier engagement, and a path that helps companies plan more effectively.

That matters for project teams.

A new or expanded facility is not just a construction project. It becomes a coordinated effort across engineering, quality, validation, automation, procurement, vendors, operations, regulatory, and executive leadership.

When those groups are not aligned early, the project can look healthy on paper while hidden issues build underneath the surface.

Sterile Capacity Shows Why Execution Matters

Sterile injectable manufacturing is one of the clearest examples of why execution discipline matters.

Recent market data shows continued growth expectations for the sterile injectables CDMO space, with demand tied to aseptic processing, complex drug products, biologics, and outsourcing needs. Resilience’s Ohio expansion also reflects the importance of integrated sterile manufacturing, device assembly, packaging, and supply chain capability.

Sterile manufacturing is complex because so many systems have to work together.

Facilities must support contamination control. Clean utilities must be available and reliable. Equipment must be installed and tested correctly. Automation must support the process. Environmental controls must be verified. Procedures must be approved. Operators must be trained. Quality reviews must move on time. Vendor documentation must be complete. Turnover packages must support commissioning, qualification, validation, and operations.

A delay in one area can quickly affect the whole startup path.

That is why capacity expansion cannot be treated as a sequence of disconnected workstreams. It needs integrated execution from the beginning.

The Project Risk Is Often Hidden in the Handoffs

Manufacturing projects do not usually struggle because no one cares.

They struggle because critical handoffs are unclear.

Who owns vendor documentation follow-up?
Who is tracking turnover readiness?
Who is making sure automation changes are reflected in testing?
Who is checking whether training supports the actual startup schedule?
Who is making sure quality review timelines are realistic?
Who is connecting project controls to readiness risk, not just schedule status?

These are practical questions, but they determine whether a project moves smoothly or stalls.

In highly regulated environments, the handoff between construction, commissioning, qualification, validation, and operations is especially important. If C&Q or C&V is treated as an end-stage paperwork activity, teams may find themselves trying to recover readiness late in the project.

That creates pressure, rework, frustration, and schedule risk.

The better approach is to build readiness into the project from the start.

Documentation Is Not Paperwork, It Is Execution Infrastructure

As domestic manufacturing expands, documentation will become even more important.

User requirements, design documents, vendor packages, FAT/SAT records, commissioning records, qualification protocols, validation evidence, training records, deviations, SOPs, risk assessments, traceability matrices, turnover packages, and approval workflows all help teams prove readiness.

When documentation is late, incomplete, unclear, or disconnected from the actual field condition, the project loses control.

Good documentation is not just for auditors.

It helps teams make decisions, confirm scope, transfer knowledge, manage risk, and sustain operations after startup.

For medical device manufacturers, the documentation burden is also shaped by the FDA’s Quality Management System Regulation, which became effective in February 2026 and incorporates ISO 13485:2016 into U.S. quality system requirements. That makes quality-system alignment, supplier controls, production readiness, and inspection preparation even more important for device manufacturers operating in the current regulatory environment.

What This Means for Life Sciences Leaders

Domestic manufacturing investment is good news for the industry, but it creates a new challenge for leaders: execution capacity.

Companies need more than facilities and equipment. They need teams that can connect strategy to delivery.

That means stronger project controls. Earlier C&Q and C&V planning. Clearer vendor management. Better documentation discipline. More realistic readiness reviews. Stronger handoffs between engineering, quality, validation, automation, and operations. Better visibility into what is truly ready and what is only green on a dashboard.

This is where Persperity’s work fits.

Persperity is an execution-focused professional services firm supporting complex projects in highly regulated environments. The company is not built to simply provide recommendations and leave clients with a deck. Persperity supports the hands-on work that helps teams move from plan to production.

As domestic pharma manufacturing continues to grow, the companies that succeed will not only be the ones that announce new capacity. They will be the ones that can bring that capacity online with discipline, clarity, quality, and readiness.

That is the difference between building a facility and delivering manufacturing capability.